NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (AMEX:SNT) today announced that it has entered into a Master Services Agreement with Cato Research Ltd. (“Cato”), a contract research and development organization (“CRO”), to assist the Company in evaluating and developing the Company’s technology with the ultimate goal of initiating a Phase I clinical trial for a certain cancer.
